Eichenauer, Dennis A <br/><br/>
Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.  [electronic resource] 

 -  The Lancet. Oncology  12 2017 
 - 1680-1687 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1474-5488 
<br/><br/><label>Standard No.: </label>10.1016/S1470-2045(17)30696-4  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Bleomycin--administration & dosage<br/>Brentuximab Vedotin<br/>Confidence Intervals<br/>Cyclophosphamide--administration & dosage<br/>Disease-Free Survival<br/>Dose-Response Relationship, Drug<br/>Doxorubicin--administration & dosage<br/>Drug Administration Schedule<br/>Etoposide--administration & dosage<br/>Female<br/>Germany<br/>Hodgkin Disease--drug therapy<br/>Humans<br/>Immunoconjugates--administration & dosage<br/>Kaplan-Meier Estimate<br/>Male<br/>Middle Aged<br/>Neoplasm Invasiveness--pathology<br/>Neoplasm Staging<br/>Predictive Value of Tests<br/>Prednisone--administration & dosage<br/>Procarbazine--administration & dosage<br/>Prognosis<br/>Prospective Studies<br/>Risk Assessment<br/>Survival Analysis<br/>Treatment Outcome<br/>Vincristine--administration & dosage